Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COLLNASDAQ:IMMPNASDAQ:MLYSNASDAQ:NTLA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$29.23-0.3%$28.00$23.23▼$42.29$939.22M0.63421,106 shs323,265 shsIMMPImmutep$1.86-0.3%$1.75$1.32▼$2.86$270.90M1.8217,222 shs113,532 shsMLYSMineralys Therapeutics$16.18+3.1%$14.42$8.24▼$18.38$1.05B-0.3497,885 shs698,785 shsNTLAIntellia Therapeutics$7.69+7.4%$7.90$5.90▼$28.18$796.55M2.332.72 million shs5.71 million shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical-0.27%-0.85%+5.71%+2.67%-9.42%IMMPImmutep-0.27%-6.78%+8.48%+3.63%-37.75%MLYSMineralys Therapeutics+3.06%+2.86%+4.93%+61.64%+23.70%NTLAIntellia Therapeutics+7.40%-17.49%-13.01%-17.84%-67.30%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOLLCollegium Pharmaceutical4.1646 of 5 stars3.40.00.03.04.20.82.5IMMPImmutep1.2886 of 5 stars3.51.00.00.02.30.00.0MLYSMineralys Therapeutics2.7545 of 5 stars3.51.00.00.02.95.00.0NTLAIntellia Therapeutics4.6307 of 5 stars4.31.00.04.73.12.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOLLCollegium Pharmaceutical 2.80Moderate Buy$43.8049.85% UpsideIMMPImmutep 3.00Buy$7.00277.36% UpsideMLYSMineralys Therapeutics 3.00Buy$38.00134.86% UpsideNTLAIntellia Therapeutics 2.67Moderate Buy$34.95354.49% UpsideCurrent Analyst Ratings BreakdownLatest IMMP, COLL, MLYS, and NTLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025NTLAIntellia TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$74.00 ➝ $54.005/29/2025NTLAIntellia TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral$10.00 ➝ $7.005/29/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.005/20/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/19/2025NTLAIntellia TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$10.00 ➝ $10.005/14/2025MLYSMineralys TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$48.005/13/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.005/12/2025NTLAIntellia TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $45.005/9/2025COLLCollegium PharmaceuticalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$36.00 ➝ $37.005/9/2025NTLAIntellia TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$14.00 ➝ $10.005/9/2025NTLAIntellia TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$68.00 ➝ $68.00(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOLLCollegium Pharmaceutical$664.28M1.41$10.59 per share2.76$5.99 per share4.88IMMPImmutep$5.14M52.70N/AN/A$1.05 per share1.77MLYSMineralys TherapeuticsN/AN/AN/AN/A$3.84 per shareN/ANTLAIntellia Therapeutics$45.57M17.48N/AN/A$11.73 per share0.66Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOLLCollegium Pharmaceutical$48.15M$1.2212.604.86N/A14.78%104.67%18.38%8/14/2025 (Estimated)IMMPImmutep-$28.01MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)MLYSMineralys Therapeutics-$177.81M-$3.73N/AN/AN/AN/A-67.97%-62.40%8/12/2025 (Estimated)NTLAIntellia Therapeutics-$481.19M-$5.23N/AN/AN/AN/A-49.34%-40.27%8/14/2025 (Estimated)Latest IMMP, COLL, MLYS, and NTLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025MLYSMineralys Therapeutics-$1.02-$0.79+$0.23-$0.79N/AN/A5/8/2025Q1 2025COLLCollegium Pharmaceutical$1.50$1.49-$0.01$0.07$174.96 million$177.76 million5/8/2025Q1 2025NTLAIntellia Therapeutics-$1.26-$1.10+$0.16-$1.10$11.39 million$16.63 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOLLCollegium PharmaceuticalN/AN/AN/AN/AN/AIMMPImmutepN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOLLCollegium Pharmaceutical3.430.970.88IMMPImmutep0.0118.2518.25MLYSMineralys TherapeuticsN/A14.0214.02NTLAIntellia TherapeuticsN/A6.736.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOLLCollegium PharmaceuticalN/AIMMPImmutep2.32%MLYSMineralys Therapeutics84.46%NTLAIntellia Therapeutics88.77%Insider OwnershipCompanyInsider OwnershipCOLLCollegium Pharmaceutical2.51%IMMPImmutep3.07%MLYSMineralys Therapeutics25.56%NTLAIntellia Therapeutics3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOLLCollegium Pharmaceutical21032.13 million30.97 millionOptionableIMMPImmutep2,021146.04 million141.09 millionOptionableMLYSMineralys Therapeutics2865.18 million33.27 millionOptionableNTLAIntellia Therapeutics600103.58 million98.59 millionOptionableIMMP, COLL, MLYS, and NTLA HeadlinesRecent News About These CompaniesCanaccord Genuity Group Issues Pessimistic Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock PriceJune 3 at 8:11 AM | marketbeat.comNuveen Asset Management LLC Decreases Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)June 3 at 3:36 AM | marketbeat.comEvercore ISI Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)June 1 at 11:18 AM | theglobeandmail.comSquarepoint Ops LLC Has $1.18 Million Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)June 1 at 4:00 AM | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Shares Down 5.6% - Here's What HappenedMay 31, 2025 | marketbeat.comSA analyst downgrades: PLTR, PSTG, NTLA, ARWRMay 30, 2025 | msn.comIntellia shares tumble on safety signal in gene-editing trialMay 30, 2025 | thepharmaletter.comIntellia Therapeutics (NASDAQ:NTLA) Shares Up 4.7% - Here's What HappenedMay 30, 2025 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Receives Neutral Rating from WedbushMay 30, 2025 | marketbeat.comNTLA Stock Down as Patient Faces Adverse Event in Gene Therapy StudyMay 30, 2025 | zacks.comIntellia Therapeutics (NASDAQ:NTLA) Shares Gap Down - What's Next?May 30, 2025 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Receives "Buy" Rating from HC WainwrightMay 30, 2025 | marketbeat.comIntellia Therapeutics' (NTLA) "Neutral" Rating Reaffirmed at WedbushMay 30, 2025 | americanbankingnews.comIntellia: Heart Disease Safety Setback Triggers Selloff - Caution AdvisedMay 29, 2025 | seekingalpha.comIntellia Therapeutics Stock Plummets After Adverse Event In Gene Editing Therapy Study: But Retail’s Buying The DipMay 29, 2025 | msn.comAnalysts Brush Off Intellia’s Adverse Event but Gene Therapy Safety Concerns ContinueMay 29, 2025 | biospace.comIntellia Shares Drop 19% After Safety Signal Emerges in Phase 3 TrialMay 29, 2025 | msn.comDemystifying Intellia Therapeutics: Insights From 9 Analyst ReviewsMay 29, 2025 | benzinga.comIntellia's stock sinks on gene therapy patient's raised enzyme levels, but analysts keep faithMay 29, 2025 | fiercebiotech.comIntellia filing spurs safety concerns over CRISPR drugMay 29, 2025 | biopharmadive.comIntellia stock tumbles on safety concernsMay 29, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMMP, COLL, MLYS, and NTLA Company DescriptionsCollegium Pharmaceutical NASDAQ:COLL$29.23 -0.08 (-0.27%) Closing price 06/3/2025 04:00 PM EasternExtended Trading$29.24 +0.02 (+0.05%) As of 06/3/2025 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Immutep NASDAQ:IMMP$1.86 -0.01 (-0.27%) Closing price 06/3/2025 04:00 PM EasternExtended Trading$1.86 0.00 (0.00%) As of 06/3/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.Mineralys Therapeutics NASDAQ:MLYS$16.18 +0.48 (+3.06%) Closing price 06/3/2025 04:00 PM EasternExtended Trading$15.96 -0.22 (-1.33%) As of 06/3/2025 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Intellia Therapeutics NASDAQ:NTLA$7.69 +0.53 (+7.40%) Closing price 06/3/2025 04:00 PM EasternExtended Trading$7.66 -0.03 (-0.40%) As of 06/3/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Reasons Amazon Could Be the Best Tech Performer in June Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Applied Digital: CoreWeave’s AI Deal Lights a $7 Billion Fuse Qualcomm: A Technical Deep-Dive Confirms the Worst Rocket Lab Expands Into Payloads: Should You Be Paying Attention? Steel Dynamics Shares Climb After Tariff Announcement Palantir Soars on Government Deals as Valuation Debate Lingers Broadcom Earnings Preview: AVGO Stock Near Record Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
